Ceva Animal Health has announced the launch of Cardalis, a “unique combination of benazepril and spironolactone” licensed to treat heart failure caused by degenerative valvular heart disease in dogs.
Ceva Animal Health has announced the addition of a new product to its portfolio, which is licensed to treat heart failure caused by degenerative valvular heart disease in dogs.
According to the company, Cardalis contains a unique combination of benazepril and spironolactone in one tablet which provides “dual blockade” of the RAAS system.
- Benazepril reduces the production of angiotensin II, which causes narrowing of the blood vessels.
- Spironolactone blocks the harmful effects of aldosterone, which include cardiovascular remodelling and fibrosis.
Cardalis tablets are small, beef flavoured and designed to be administered once a day with food. Each pot contains 30 tablets and there are three sizes available.
The product should be given as part of standard heart failure therapy as soon as clinical signs, such as exercise intolerance, coughing or dyspnoea, appear.
Ceva small animal product manager Fraser Broadfoot said: “Through our clinical studies, it has been found that dogs receiving benazepril and spironolactone (compared with benazepril alone) have a better quality of life and, at any one time, are three times less likely to die from heart failure.”
- To receive marketing materials (including a waiting room poster and client information booklets) or for further information on Cardalis visit www.ceva.co.uk or contact the practice support team on 01494 781510.